Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?

Urothelial bladder cancer is one of the most lethal cancers worldwide with barely 5% five-year survival in patients with metastatic disease. Intravesical immunotherapy with <i>Bacillus Calmette-Guérin</i> and platinum-based chemotherapy are currently the standard of care for non-muscle i...

Full description

Bibliographic Details
Main Authors: Giandomenico Roviello, Martina Catalano, Stefania Nobili, Raffaella Santi, Enrico Mini, Gabriella Nesi
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:International Journal of Molecular Sciences
Subjects:
PD-1
PD-L1
bladder cancer
biomarkers
Online Access:https://www.mdpi.com/1422-0067/21/21/7935

Similar Items

Similar Items